Clinical Trials

31 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03809780 2023-06-22

LENDER

70 enrolled

Multiple Myeloma

NCT03641456 2023-06-18

VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

50 enrolled

Neoplasms, Plasma Cell

NCT04941937 2023-02-27

Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

90 enrolled

Multiple Myeloma

NCT04113226 2023-02-08

Relyage

114 enrolled

LymphoidSarcoma

Recurrence, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT05182957 2023-01-31

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

40 enrolled

Lymphoma, T-Cell, Peripheral

NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

53 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT05575973 2022-10-12

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

55 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03891355 2022-09-15

FIL_KLIMT

16 enrolled

Lymphoma, Mantle-Cell

NCT04277845 2022-09-09

KMM1910

49 enrolled

Multiple Myeloma

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

51 enrolled

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05200312 2022-03-11

ZR2-CHOP

36 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

54 enrolled

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT03837873 2022-01-26

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

118 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05076097 2021-11-11

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

29 enrolled

Lymphoma, Mantle-Cell

NCT05014100 2021-08-27

Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

55 enrolled

Lymphoma, B-Cell

NCT03949062 2021-02-17

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04025593 2020-11-19

Biomarker Guided Treatment in DLBCL

128 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04604028 2020-10-27

LCMALT

21 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT04544059 2020-09-10

Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma

87 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03669445 2020-07-30

IFM2018-01

45 enrolled

Multiple Myeloma

NCT04329130 2020-04-24

Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

44 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT03746223 2019-10-09

Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

42 enrolled

Intraocular Lymphoma

NCT02060656 2019-09-19

LEGEND

92 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03715309 2019-07-08

R2 in the Treatment of Follicular Lymphoma

115 enrolled

Lymphoma, Follicular

NCT03605056 2018-07-30

Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM

25 enrolled

Multiple Myeloma

NCT00885508 2015-04-24

GFM-Chimio-Rev

MyeloidOther hematologic neoplasm

85 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01307592 2014-01-10

Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma